uniQure N.V. (QURE) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-03-31..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-03-31..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 133.71M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 18.36M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -191.74M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $133.71M | (m) | $18.36M | $-191.74M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $140.67M | (m) | $17.68M | $-185.35M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $144.73M | (m) | $17.77M | $-180.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $140.96M | (m) | $17.68M | $-169.25M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $139.23M | (m) | $19.48M | $-169.40M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $143.78M | (m) | $22.26M | $-184.29M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $147.56M | (m) | $24.55M | $-200.21M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $182.37M | (m) | $32.21M | $-241.86M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $194.75M | (m) | $34.22M | $-262.93M | $54.09M | (m) | (m) | -4.86× | Reported |
| 2023-12-31 | $214.86M | (m) | $35.09M | $-282.87M | $41.56M | (m) | (m) | -6.81× | Reported |
| 2023-09-30 | $230.57M | (m) | $39.97M | $-194.62M | $29.27M | (m) | (m) | -6.65× | Reported |
| 2023-06-30 | $213.24M | (m) | $36.48M | $-172.26M | $16.90M | (m) | (m) | -10.20× | Reported |
| 2023-03-31 | $213.40M | (m) | $35.40M | $-163.25M | $12.75M | (m) | (m) | -12.80× | Reported |
| 2022-12-31 | $197.59M | (m) | $34.20M | $-143.16M | $11.70M | (m) | (m) | -12.23× | Reported |
| 2022-09-30 | $181.60M | (m) | $29.18M | $-167.59M | $10.38M | (m) | (m) | -16.15× | Reported |
| 2022-06-30 | $169.97M | (m) | $27.52M | $-153.07M | $9.23M | (m) | (m) | -16.58× | Reported |
| 2022-03-31 | $155.90M | (m) | $26.74M | $301.00M | $8.44M | (m) | (m) | 35.67× | Reported |
| 2021-12-31 | $143.55M | (m) | $25.64M | $310.62M | $7.47M | (m) | (m) | 41.56× | Reported |
| 2021-09-30 | $132.89M | (m) | $24.13M | $300.29M | $6.32M | (m) | (m) | 47.55× | Reported |
| 2021-06-30 | $132.76M | (m) | $24.55M | $300.80M | $5.33M | (m) | (m) | 56.40× | Reported |
| 2021-03-31 | $129.04M | (m) | $23.24M | $-135.42M | $4.40M | (m) | (m) | -30.77× | Reported |
| 2020-12-31 | $122.40M | (m) | $21.83M | $-125.43M | $3.83M | (m) | (m) | -32.79× | Reported |
| 2020-09-30 | $117.21M | (m) | $21.22M | $-150.14M | $3.84M | (m) | (m) | -39.07× | Reported |
| 2020-06-30 | $104.46M | (m) | $18.73M | $-136.98M | $3.86M | (m) | (m) | -35.48× | Reported |
| 2020-03-31 | $100.21M | (m) | $17.59M | $-128.10M | $3.83M | (m) | (m) | -33.46× | Reported |
| 2019-12-31 | $94.74M | (m) | $17.53M | $-121.14M | $3.81M | (m) | (m) | -31.80× | Reported |
| 2019-09-30 | $86.96M | (m) | $16.12M | $-112.37M | $3.52M | (m) | (m) | -31.94× | Reported |
| 2019-06-30 | $83.95M | (m) | $14.86M | $-104.27M | $3.07M | (m) | (m) | -33.93× | Reported |
| 2019-03-31 | $78.29M | (m) | $12.47M | $-96.14M | $2.70M | (m) | (m) | -35.59× | Reported |
| 2018-12-31 | $74.81M | (m) | $10.71M | $-88.23M | $2.16M | (m) | (m) | -40.85× | Reported |
| 2018-09-30 | $74.30M | $12.26M | $11.65M | $-86.67M | $2.15M | 606.04% | 95.06% | -40.41× | Reported |
| 2018-06-30 | $73.86M | $11.37M | $11.48M | $-72.72M | $2.21M | 649.52% | 100.96% | -32.95× | Reported |
| 2018-03-31 | $72.24M | $13.26M | $11.20M | $-71.23M | $2.14M | 544.60% | 84.45% | -33.22× | Reported |
| 2017-12-31 | $72.17M | $13.11M | $10.28M | $-71.34M | $2.23M | 550.64% | 78.43% | -31.96× | Reported |
| 2017-09-30 | $73.94M | $19.65M | $7.17M | $-65.09M | $2.07M | 376.22% | 36.49% | -31.44× | Reported |
| 2017-06-30 | $70.44M | $24.61M | $5.65M | $-69.98M | $2.00M | 286.18% | 22.95% | -34.99× | Reported |
| 2017-03-31 | $72.80M | $24.12M | $5.17M | $-72.40M | $2.05M | 301.77% | 21.44% | -35.37× | Reported |
| 2016-12-31 | $72.51M | $25.10M | $6.21M | $-71.95M | $2.17M | 288.91% | 24.76% | -33.12× | Reported |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $59.13M | $10.58M | $11.62M | $-71.15M | $2.57M | 558.94% | 109.82% | -27.66× | Reported |
| 2014-12-31 | $43.77M | $6.14M | $8.40M | $-53.68M | $2.02M | 712.78% | 136.72% | -26.59× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |